Two fantastic tidbits emerging out of Array Biopharma, Inc. (NASDAQ: ARRY) headquarters: Array has filed an Investigational New Drug application for ARRY-797 with the FDA and is now able to proceed with human clinical studies. ARRY-797 is a potent, selective, orally active inhibitor of p38 MAP kinase and has demonstrated good tolerability and significant efficacy [...]

• 133http://clsdf.com/2006/11/array-biopharma-phase-i-data-ind/Array+Biopharma%3A+Phase+I+Data+%26amp%3B+IND2006-11-06+17%3A28%3A00admin

InViragen (Ft. Collins), who is developing vaccines against emerging world-wide diseases such as West Nile, avian influenza, plague and smallpox, has announced a vaccine manufacturing agreement with Shantha Biotechnics (Hyderabad, India) to develop their lead dengue vax product to enable completion of preclinical studies and initiate safety and efficacy clinical trials. Since winning the first [...]

• 132http://clsdf.com/2006/11/inviragen-agreemnent-with-shantha-bio/InViragen%3A+Agreemnent+with+Shantha+Bio2006-11-06+16%3A50%3A00admin